David Chen
Impact in
- Cancer Research top 2%
- Cancer Genomics and Diagnostics
- Oncology top 2%
- HER2/EGFR in Cancer Research
Papers in
-
- Renal cell carcinoma treatment 19
- Lung Cancer Treatments and Mutations 7
-
- Renal and related cancers 11
- Co-authors
- José Baselga (4 shared papers)Sarat Chandarlapaty (3 shared papers)Gabriel N. Hortobágyi (4 shared papers)Maurizio Voi (9 shared papers)Michael F. Berger (3 shared papers)Yang Shen (1 shared paper)Marie Will (1 shared paper)Clifford A. Hudis (1 shared paper)
- Journals
- Journal of Clinical Oncology (27 papers)The Journal of Urology (8 papers)The American Surgeon (2 papers)Cell Metabolism (1 paper)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesCanadaSwitzerland
In The Last Decade
David Chen
74 papers receiving 3.6k citations
David Chen's Hit Papers
Peers
Comparison fields: 5 of 128
- Cancer Research 877
- Oncology 1.4k
- Pulmonary and Respiratory Medicine 1.5k
- Physiology 606
- Molecular Biology 1.4k
Countries citing papers authored by David Chen
This map shows the geographic impact of David Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Chen more than expected).
Fields of papers citing papers by David Chen
This network shows the impact of papers produced by David Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Chen. The network helps show where David Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside David Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | ESR1 ligand-binding domain mutations in hormone-resistant breast cancer Hit paper breakdown → | 2013 | 855 |
| 2 | Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2013 | 629 |
| 3 | 2016 | 347 | |
| 4 | 2016 | 192 | |
| 5 | 2012 | 158 | |
| 6 | 2020 | 132 | |
| 7 | 2011 | 115 | |
| 8 | 2021 | 111 | |
| 9 | 2006 | 102 | |
| 10 | 2016 | 77 | |
| 11 | 2015 | 60 | |
| 12 | 2013 | 59 | |
| 13 | 1970 | 58 | |
| 14 | 2007 | 56 | |
| 15 | 2020 | 54 | |
| 16 | 2013 | 54 | |
| 17 | 2016 | 36 | |
| 18 | 2014 | 34 | |
| 19 | 2016 | 34 | |
| 20 | 2019 | 33 |
About David Chen
David Chen is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Surgery and Cancer Research, having authored 75 papers that have together received 3.6k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (19 papers), Cancer Genomics and Diagnostics (13 papers), Renal and related cancers (11 papers), Bladder and Urothelial Cancer Treatments (11 papers), Urinary and Genital Oncology Studies (7 papers), Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (6 papers) and Tuberous Sclerosis Complex Research (5 papers). The work is most often cited by research in Cancer Research (877 citations), Oncology (1.4k citations), Pulmonary and Respiratory Medicine (1.5k citations), Physiology (606 citations) and Molecular Biology (1.4k citations). David Chen has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include José Baselga, Sarat Chandarlapaty, Gabriel N. Hortobágyi, Maurizio Voi, Michael F. Berger, Yang Shen, Marie Will, Clifford A. Hudis, Weiyi Toy and Tetiana Taran. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Urology, The American Surgeon, Cell Metabolism and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.